Compass Therapeutics (CMPX) Insider Trading & Ownership $2.10 +0.05 (+2.18%) As of 02:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Compass Therapeutics (NASDAQ:CMPX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage29.80%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$30,800.00Number OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$5.68 M Get CMPX Insider Trade Alerts Want to know when executives and insiders are buying or selling Compass Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CMPX Insider Buying and Selling by Quarter Compass Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/9/2025Carl L GordonDirectorSell3,571,428$1.59$5,678,570.52 4/7/2025Jonathan AndermanInsiderBuy20,000$1.54$30,800.00 (Data available from 1/1/2013 forward) CMPX Insider Trading Activity - Frequently Asked Questions Who is on Compass Therapeutics's Insider Roster? The list of insiders at Compass Therapeutics includes Carl L Gordon, Jonathan Anderman, Orbimed Advisors Llc, Thomas J Schuetz, and Vered Bisker-Leib. Learn more on insiders at CMPX. What percentage of Compass Therapeutics stock is owned by insiders? 29.80% of Compass Therapeutics stock is owned by insiders. Learn more on CMPX's insider holdings. Which Compass Therapeutics insiders have been buying company stock? The following insider purchased CMPX shares in the last 24 months: Jonathan Anderman ($30,800.00). How much insider buying is happening at Compass Therapeutics? Insiders have purchased a total of 20,000 CMPX shares in the last 24 months for a total of $30,800.00 bought. Which Compass Therapeutics insiders have been selling company stock? The following insider sold CMPX shares in the last 24 months: Carl L Gordon ($5,678,570.52). How much insider selling is happening at Compass Therapeutics? Insiders have sold a total of 3,571,428 Compass Therapeutics shares in the last 24 months for a total of $5,678,570.52 sold. Compass Therapeutics Key ExecutivesDr. Vered Bisker-Leib M.D. (Age 53)MBA, Ph.D., CEO & Director Compensation: $719kDr. Thomas J. Schuetz M.D. (Age 63)Ph.D., Co-Founder, President of Research & Development and Vice Chairman of the Board Compensation: $835.88kMr. Neil L. Lerner CPA (Age 57)Vice President of Finance Mr. Jonathan Anderman J.D.VP, Head of Legal & Corporate Secretary1 recent tradesAnna GiffordCommunications ManagerDr. Minori Rosales M.D. (Age 61)Ph.D., Senior VP & Head of Clinical Development Ms. Karin Herrera B.A.VP & Head of Clinical OperationsDr. James Kranz Ph.D.VP and Head of Chemistry Manufacturing & Controls More Insider Trading Tools from MarketBeat Related Companies AUPH Insider Trades WVE Insider Trades GYRE Insider Trades PAHC Insider Trades MLYS Insider Trades COLL Insider Trades SNDX Insider Trades RCUS Insider Trades ELVN Insider Trades AVDL Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?Sprouts Stock: Insider Sales, But Strong Bullish Signals5 Hot Small-Cap Insiders Bought at the Peak of Tariff FearsThe Top-Ranked Insider Buys From April by Market CapMcDonald’s Insiders Sell Shares! Investors Should Do the Opposite This page (NASDAQ:CMPX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredWashington Is Broke—and Eyeing Your Savings NextWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.